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ABSTr ACT
Purpose Blockade of the angiotensin-renin system, with an-
giotensin converting enzyme inhibitors (ACEi) and angiotensin 
receptor blockers (ARBs), has been shown to improve cardiac 
outcomes following myocardial infarction and delay progres-
sion of heart failure. Acromegaly is associated with a dis-
ease-specific cardiomyopathy, the pathogenesis of which is 
poorly understood.
Methods The cardiac indices of patients with active acromeg-
aly with no hypertension (Group A, n = 4), established hyper-
tension not taking ACEi/ARBs (Group B, n = 4) and established 
hypertension taking ACEi/ARBs (Group C, n = 4) were compared 
using cardiac magnetic imaging.
Results Patients taking ACEi/ARBs had lower end diastolic 
volume index (EDVi) and end systolic volume index (ESVi) than 
the other 2 groups ([C] 73.24 vs. [A] 97.92 vs. [B] 101.03 ml/
m2, ANOVA p = 0.034, B vs. C p < 0.01). Groups A and B had EDVi 
and ESVi values at the top of published reference range values; 
Group C had values in the middle of the range.
Conclusion Acromegaly patients on ACEi/ARBs for hyperten-
sion demonstrate improved cardiac indices compared to acro-
megaly patients with hypertension not taking these medica-
tions. Further studies are needed to determine if these drugs 
have a beneficial cardiac effect in acromegaly in the absence of 
demonstrable hypertension.
Introduction
Blockade of the renin-angiotensin system, using angiotensin con-
verting enzyme inhibitors (ACEi) and angiotensin receptor block-
ers (ARBs), has been shown to reduce left ventricle (LV) remodeling 
in patients with myocardial infarction and delay the disease pro-
gression in heart failure [1–3]. Patients with growth hormone (GH) 
excess (acromegaly) develop a disease-specific cardiomyopathy as-
sociated with biventricular hypertrophy and diastolic dysfunction, 
that progresses to fulminant cardiac failure if left untreated [4–6]. 
In this preliminary study we compared the cardiac indices of 12 pa-
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tients with active acromegaly, 4 of whom had no diagnosis of hy-
pertension, 4 with an established diagnosis of hypertension on ACEi 
or ARBs and 4 with an established diagnosis of hypertension not 
taking these classes of drugs. Cardiac indices were compared using 
cardiac magnetic resonance imaging (CMR).
Material and Methods
12 patients with active acromegaly (clinical features, raised insulin-like 
growth factor 1 [IGF1] and failure to suppress GH on oral glucose tol-
erance testing) who were about to commence therapy underwent 
CMR to assess cardiac function and morphology: LV mass index (LVMi); 
end diastolic volume index (EDVi); end systolic volume index (ESVi); 
ejection fraction (EF). Measurements were indexed to body surface 
area. CMR was performed on a Philips Achieva CV 1.5 Tesla MRI scan-
ner (Philips Medical Systems, Guildford, UK). Standard protocols were 
used. In this observational study, patients were divided into 3 groups: 
those with no known history of hypertension (A); those with a known 
diagnosis of hypertension not currently taking ACEi/ARB (B) and those 
with a known diagnosis of hypertension taking ACEi/ARB (C). Groups 
B and C patients may also have been taking additional antihyperten-
sive medication (▶Table 1). Weight, height and blood pressure, serum 
IGF1 and fasting glucose levels were recorded. Patients with known 
ischaemic heart disease or heart failure were excluded. Multi-centre 
ethical approval was given by the local Research Ethics Committee 
(06/Q0401/53). Statistics were calculated using ANOVA with Bonfer-
roni correction.
Results
Patient characteristics are given in ▶Table 2, with no significant 
difference in IGF-1, blood pressure and fasting glucose. Group C 
patients were older and tended to have higher baseline blood pres-
sure values than the other 2 groups. There was no difference in LVMi 
between the 3 groups. No patient had evidence of frank heart fail-
ure (all had an EF within normal limits). Patients in Group C had 
lower EDVi and ESVi than the other 2 groups (▶Fig. 1). Patients in 
Groups A and B had EDVi and ESVi values at the top of published 
reference range values. Patients in Group C had values in the mid-
dle of the reference range [7].
Discussion
This preliminary study indicated that patients taking ACEi/ARBs had 
lower end diastolic volume index (EDVi) and end systolic volume index 
(ESVi) than the other 2 groups including patients with no hyperten-
sion or hypertension treated with other drugs. While patients in group 
C were older and tended to have a higher mean blood pressure than 
groups A and B, this, if anything, should have increased the preva-
lence of cardiac remodeling in this group whereas the converse was 
seen with reduced remodeling, adding more evidence to the sugges-
tion that ACEi/ARBs were influential in reducing EDVi and ESVi.
EDVi and ESVi are markers of cardiac remodeling, the process of 
change in size, shape and function of the heart, arising from cardiac 
load or injury [8]. As this process continues, heart failure develops and 
a reduction in EF is seen. ACEi and ARBs have been shown to delay pro-
gression of ischaemic heart failure and to improve survival through 
prevention and possible reversal of this remodeling process [1, 3, 9, 10].
The reasons for the improvement in LV EDVi and ESVi in patients 
treated with ACEi/ARBs are likely to be multifactorial. Firstly, acro-
megalic cardiomyopathy appears to be more marked in patients 
who have concurrent hypertension [11]. Additionally, acromegaly 
may be associated with increased serum aldosterone levels [12]. 
Blockade of the renin-angiotensin pathway will reduce the effects 
of aldosterone excess, reducing cardiac pre-load and possibly local 
myocardial response to aldosterone excess, thought to play a part 
in promoting remodeling [8]. Furthermore, it has been found that 
ACEi can attenuate the ability of IGF1 to produce cardiac fibroblast 
proliferation, indicating that these medications may have a direct 
effect on the response of the myocardium to GH action, directly 
inhibiting the development of acromegalic cardiomyopathy [13].
This study did not demonstrate any reduction in LVMi associat-
ed with ACEi/ARB use, although this may be related to group size. 
Given the changes seen in EDVi and ESVi, and the lower mean LVMi 
in group C compared to group B, it would be interesting to address 
this in a larger study.
It should be noted that ACEi are not more efficacious in reducing 
cardiovascular morbidity or mortality than other forms of anti-hyper-
tensive medications in patients without acromegaly [14]. However, 
the changes seen in this preliminary study suggest that patients with 
acromegaly may derive benefits from these medications over and 
above those arising simply from the normalisation of hypertension.
▶Table 1 List of anti-hypertensives patients were on.
Group B Group C
Patient Anti-hypertensives Patient Anti-hypertensives
5 Bendrofluazide 3 Ramipril
7 Amiloride  
Cyclopenthiazide
4 Ramipril  
Bendrofluazide
9 Atenolol 10 Ramipril
11 None 12 Losartan  
Amlodipine  
Doxazosin
▶Table 2 Patient characteristics. Data given as group mean and [SD]. BP – blood pressure.
Group A (n = 4) Group B (n = 4) Group C (n = 4) P-value
Number of females 2/4 3/4 3/4 N/A
Age (years) 41.8 [7.6] 54.5 [10.6] 62.8 [11.2] 0.043
IGF1 (SDS) 11.1 [5.5] 19.0 [17.2] 14.4 [11.1] 0.669
Systolic BP (mmHg) 125 [26] 133 [23] 147 [15] 0.392
Diastolic BP (mmHg) 74 [17] 76 [12] 82 [6] 0.655
Fasting Glucose (mmol/L) 5.5 [0.82] 5.1 [0.44] 5.8 [1.13] 0.483
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The main limitation of this study is the small sample size. We 
note that the study was open to several large UK centres for 3 years 
and this was the number of acromegaly patients who fulfilled in-
clusion criteria and agreed to take part in the study. In such a rare 
condition, greater number of patients is often difficult to achieve. 
Albeit a small sample, these are the first data suggesting that ACEi/
ARBs may have a significant benefit in acromegaly patients over 
and above normalisation of blood pressure.
Conclusion
In this preliminary study, acromegaly patients with hypertension tak-
ing ACEi/ARBs demonstrated evidence of less cardiac remodeling than 
those taking alternative anti-hypertensives. We suggest that these 
agents should be considered first line anti-hypertensives in patients 
with this diagnosis. Larger studies are needed to confirm these findings 
and determine if there is a role using these medications in patients with 
active acromegaly who have not yet developed hypertension.
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▶Fig. 1 Graph comparing EDVi and ESVi in the 3 groups. There is a significant difference (p < 0.01) between Group B and Group C. Error bars indicate SEM.
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